Kang X, Wang D, Zhang L, Huang T, Liu S, Feng X, et al
The United States set 0.08% BAC as the legal limit
Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
SELENOP is essential for selenium supply to the testes, and animal models lacking the SELENOP gene are infertile due to poor selenium tissue bioavailability, defective GPx4 synthesis, and impaired sperm maturation (7)
GLP-1 drugs help regulate blood sugar, offering a dual benefit